NOW RECRUITING: Patients with Pulmonary Arterial Hypertension (PAH) for IMPAHCT,
a Phase 2b/3 study evaluating AV-101. Learn more about the study.

Allison Dorval

Allison is the chief financial officer of Verve Therapeutics, and is a member of the Board of Directors of Puma Biotechnology, Inc. She has more than 20 years of corporate finance, accounting and operating experience, including 14 years of life sciences executive finance experience. Prior to joining Verve, Allison served as chief financial officer of Voyager Therapeutics, vice president, controller, at Juniper Pharmaceuticals, Inc., and as chief financial officer at Insulet Corporation, where she led financial planning, reporting and accounting. Previously, Ms. Dorval held corporate finance positions with iBasis, Inc. and Digitas Inc. Ms. Dorval is a certified public accountant and began her career in public accounting at PriceWaterhouseCoopers LLP, where she held positions of increasing responsibility and scope. Ms. Dorval obtained a Bachelor of Science in Business Administration from the University of Vermont.